INTRODUCTION {#ss1}
============

Dementia with Lewy bodies (DLB) is a common form of dementia in the elderly, and constitutes the second largest group of patients with dementia after Alzheimer disease (AD).[@b1] The core clinical features of DLB include neuropsychiatric symptoms and motor symptoms of parkinsonism as well as cognitive impairment characterized by deficits of attention, executive function, and visual perception.[@b2] Fluctuating cognition, hallucinations, and delusions are major sources of difficulties and distress for both patients and caregivers. The motor and autonomic features further impair activities of daily living and lead to poorer quality of life.[@b3], [@b4] However, pharmacological management of DLB remains challenging, because it is complicated by the risk of adverse reactions to medication.[@b5] Treatments for one aspect of the disease may exacerbate other symptoms. It is well recognized that DLB patients can be exquisitely sensitive to antipsychotic agents and can develop life-threatening sensitivity reactions.[@b6] Antiparkinson medication given to improve motor symptoms can exacerbate neuropsychiatric symptoms such as hallucinations. There are no approved treatments for DLB.

Cholinergic loss in DLB is associated with deficits in attention and cognition, and also with neuropsychiatric symptoms.[@b7] Neuropathological and neuroimaging studies have demonstrated that cholinergic neurotransmission is more defective in DLB than in AD.[@b8] Although cholinergic losses in DLB affect both brainstem and basal forebrain presynaptic nuclei, in contrast to AD, postsynaptic cortical muscarinic and nicotinic receptors are more functionally intact,[@b9] suggesting that cholinesterase inhibitors (ChEIs) may be potent for DLB. Case reports and open-label studies have demonstrated the benefit of galantamine, rivastigmine, and donepezil on cognitive and behavioral symptoms in DLB.[@b10; @b11; @b12; @b13; @b14] However, only 1 randomized placebo-controlled trial (RCT) has been reported, in which it was suggested that rivastigmine improved attentional and behavioral symptoms.[@b15] Memantine, an N-methyl-[D]{.smallcaps}-aspartate receptor antagonist, was also tested in 2 RCTs including DLB patients; however, the results were equivocal.[@b16], [@b17] Therefore, there is very little evidence for pharmacotherapy in this group. The aim of this phase 2 study was to exploratively investigate the efficacy and safety of donepezil hydrochloride, in 3 different doses compared to placebo, in patients with DLB. This study was registered as number NCT00543855.

Patients and Methods {#ss2}
====================

Patients {#ss2-1}
--------

Patients who met the consensus diagnostic criteria[@b2] for probable DLB were recruited from 48 psychiatric or neurological specialty centers throughout Japan from October 2007 to February 2010. Diagnosis of each patient was validated after discussion by the central committee. Outpatients (≥50 years old) with mild to moderate-severe dementia (10-26 on the Mini-Mental State Examination \[MMSE\][@b18] and Clinical Dementia Rating[@b19] ≥0.5) and with behavioral symptoms (Neuropsychiatric Inventory-plus \[NPI-plus\] ≥8) were eligible. NPI-plus is a 12-item version of the NPI, with the original 10 items supplemented by 2 DLB-relevant domains of sleep and cognitive fluctuation.[@b11], [@b20], [@b21] Patients had caregivers who routinely stayed with them at least 3 days per week and 4 hours per day, provided information for this study, assisted compliance with treatment, and escorted patients to required visits.

Exclusion criteria included Parkinson disease diagnosed at least 1 year prior to the onset of dementia; focal vascular lesions on magnetic resonance imaging or computed tomography that might cause cognitive impairment; other neurological or psychiatric diseases; clinically significant systemic disease; complications or history of severe gastrointestinal ulcer, severe asthma, or obstructive pulmonary disease; systolic hypotension (\<90mmHg); bradycardia (\<50m^−1^); sick sinus syndrome; atrial or atrioventricular conduction block; QT interval prolongation (≥450 milliseconds); hypersensitivity to donepezil or piperidine derivatives; severe parkinsonism (Hoehn and Yahr score ≥ IV)[@b22]; and treatment with ChEIs or any investigational drug within 3 months prior to screening. ChEIs, antipsychotic agents, and antiparkinson drugs other than L-dopa or dopamine agonists were not allowed during the study.

Written informed consent was obtained from the patient (if at all possible) and his/her caregiver before initiating the study procedures. The study was conducted in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the institutional review board at each center.

Randomization and Masking {#ss2-2}
-------------------------

This was a multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Treatment lasted 14 weeks, including a 2-week prerandomization period followed by a 12-week randomization period. All participants were given placebo tablets during the prerandomization period, after which the patients were randomly assigned in a 1:1:1:1 ratio to placebo, 3, 5, or 10mg of donepezil. The randomization list was computer-generated using a randomized block design to allocate several blocks (size 4) to each center. Patients were sequentially assigned to the lowest randomization number available at the time of each enrollment at each center. The randomization list was securely managed by an allocation officer, who was independent of all parties concerned with the study, at Bellsystem24, Tokyo, Japan, until study completion. Access to the list was not allowed except in emergency. Study personnel and participants were unaware of the treatment assignment. During the study period, the code was broken for 2 patients: 1 each in the placebo and 3mg arms because of serious adverse events (pelvic fracture and subarachnoid hemorrhage, respectively).

Patients received 2 study drug tablets, which were composed of a combination of 3mg, 5mg, or matched placebo tablets with the same physical appearance, once daily in the morning. Dosage was titrated at the beginning of the randomization period in the 5 and 10mg groups. In the 5mg group, treatment began with 3mg for 2 weeks, and then the dose was increased to 5mg. The 10mg group started with 3mg for 2 weeks, followed by 5mg for 4 weeks, after which the 10mg dose was provided for 6 weeks. The dose was escalated after patient safety was confirmed by telephone interview.

Procedures {#ss2-3}
----------

This study had no formal predefined primary endpoint. However, cognition, behavior, global function, and caregiver burden were determined as core efficacy outcomes prior to the study initiation.

Efficacy was assessed at baseline and weeks 4, 8, and 12. Cognition was assessed using the MMSE.[@b18] In addition, 3 cognitive domains (attentive, executive, and visuoperceptual functions) relevant to DLB were assessed using the Wechsler Memory Scale-Revised (WMS-R) attention/concentration subscale,[@b23] the Verbal Fluency test (category and letter),[@b24] the Wechsler Adult Intelligence Scale (WAIS-III) symbol digit modalities subscale,[@b25] and the Visual Perception Test for Agnosia form discrimination and overlapping figure identification subscales.[@b26]

Behavior was assessed using the NPI-plus (the original NPI-10 consisting of 10 behavioral domains; ie, delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, supplemented by 2 DLB-relevant domains of sleep and cognitive fluctuation).[@b11], [@b20], [@b21] The questions in the cognitive fluctuation domain were arranged according to those reported in the literature.[@b27], [@b28] In addition to the NPI-10 and each domain of the NPI-plus, a 2-item subscore (NPI-2) was calculated as the sum of scores for hallucinations and cognitive fluctuation, which correspond to the core features of DLB in the consensus criteria, and a 4-item subscore (NPI-4) calculated as the sum of scores for delusions, hallucinations, apathy, and depression, which were reported as the main DLB symptom cluster in the previous rivastigmine study.[@b15]

Changes in global clinical status were assessed by an experienced clinician who was not involved in patient management or other assessments, using the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), with 7 grades ranging from Marked Improvement to Marked Worsening.[@b29]

Caregiver burden was assessed using the Zarit Caregiver Burden Interview (ZBI), which evaluates the physical, psychological, and social consequences of caring activities.[@b30] The ZBI contains 22 items scored from 0 (best) to 4 (worst), from which a total score from 0 to 88 is calculated.

Motor function was assessed as a safety measure using the Unified Parkinson's Disease Rating Scale (UPDRS) part III at baseline and week 12.[@b31] Safety was also assessed on the basis of adverse events (AEs), vital signs, electrocardiogram, and laboratory tests.

Statistical Analyses {#ss2-4}
--------------------

The sample size was originally defined as 160 patients (40 in each arm) on the basis of feasibility considerations. However, because of recruitment difficulties, the sample size was reduced to 140. Although no formal calculation of power was performed, this number of patients should have provided a roughly 80% power to detect a 40% difference in responder rates (see definition below) between the active and placebo arms with a 2-sided significance level of 0.0167.

The safety analysis set comprised all patients who received at least 1 dose and had a postbaseline safety assessment. Efficacy analyses were performed on the full analysis set, which consisted of all patients who had at least 1 valid postbaseline assessment on any of the efficacy scales, with the last observation carried forward (LOCF).

Imbalances in baseline demographics and background characteristics were assessed by analysis of variance (ANOVA), Kruskal-Wallis test, or chi-square test, with a 2-sided significance level of 0.15.

For efficacy, mean changes from the baseline in each outcome measure other than CIBIC-plus were compared between each active group and placebo by both Student *t* test and analysis of covariance (ANCOVA), with baseline values (sex, weight, and each test score) as covariates. In addition to the LOCF analysis, the mixed-effect model for repeated measures was applied to analyze data with dropouts as the secondary approach. For CIBIC-plus, the Wilcoxon rank sum test was used to compare the grade distributions between each active group and placebo. In addition, the MMSE and CIBIC-plus were analyzed by number of responders, defined as a ≥3 point improvement on the MMSE and as -minimal improvement- or better on the CIBIC-plus. Fisher exact probability test was used to compare each active group to placebo. The dose-response relationship (linear or 5mg saturation) across the 3 doses was also analyzed, as a secondary analysis, by ANOVA with contrasts for the MMSE and NPI, and by Cochran-Armitage test with contrasts for the CIBIC-plus. Significance levels were set at 2-sided 0.0167 for comparison with placebo (multiplicity adjustment by Bonferroni method) and 2-sided 0.05 for trend analysis.

The incidence of AEs was calculated, and group differences were examined by Fisher exact probability test. For laboratory parameters and vital signs, descriptive statistics and frequency distributions were calculated. UPDRS part III scores were compared between each active group and placebo by both Student *t* test and ANCOVA, with baseline values as covariates. Significance level was set at 2-sided 0.05 for safety analysis.

All analyses were made on SAS version 9.1.3 (SAS Institute, Cary, NC).

Results {#ss3}
=======

Patients {#ss3-1}
--------

Of the 167 patients screened in the prerandomization period, 140 were randomized to the 4 groups (35, 35, 33, and 37 to placebo, 3mg, 5mg, and 10mg, respectively). In the randomization period, 1 patient in the placebo group was withdrawn before receiving the study drug due to refusal, and was excluded from the safety analysis set. Two patients (1 each in the placebo and 10mg groups) who did not meet probable DLB criteria and 2 patients (1 each in the placebo and 5mg groups) with no postbaseline efficacy assessments were excluded from the full analysis set. Thus, the safety analysis set included 139 patients (34, 35, 33, and 37 in the placebo, 3mg, 5mg, and 10mg groups, respectively), and full analysis set included 135 patients (32, 35, 32, and 36, respectively). Sixteen patients (4, 4, 2, and 6, respectively) withdrew during the study; LOCF was applied to them ([Fig 1](#fig01){ref-type="fig"}). In the 10mg group, 3 patients discontinued during the titration phase: 1 at the 3mg/day and 2 at the 5mg/day period.

![Patient disposition. SAS = safety analysis set.](ana0072-0041-f1){#fig01}

Baseline patient characteristics are summarized in Table [1](#tbl1){ref-type="table"}. The 4 groups were similar for demographic and disease-related characteristics, although significant differences were found in the distributions of women and men, and mean body weight. Because women predominated, mean body weight was lower in the 10mg group. Some patients were taking L-dopa, dopamine agonists, antidepressants, or benzodiazepines at baseline. However, the proportion of each medication was not different among groups. Baseline scores of the cognitive and behavioral scales were also comparable, although the mean NPI-10 score was lower in the 5mg group, and the WAIS-III symbol digit score was lower in the placebo group ([Table 2](#tbl2){ref-type="table"}).

###### 

Baseline Characteristics of Patients (Full Analysis Set)

  Characteristic                                            Treatment Group               *p*                                                  
  --------------------------------------------------------- ----------------------------- ------------- ------------ ------------ ------------ -------
  Age, yr                                                   78.6 (4.7)                    79.6 (4.5)    77.9 (6.8)   78.6 (6.1)   0.663        
  Sex                                                                                                                             0.001        
  Male                                                      9 (28.1%)                     17 (48.6%)    16 (50.0%)   4 (11.1%)                 
  Female                                                    23 (71.9%)                    18 (51.4%)    16 (50.0%)   32 (88.9%)                
  Weight, kg                                                47.5 (9.0)                    51.3 (10.1)   49.6 (9.6)   44.9 (9.2)   0.035        
  CDR                                                                                                                             0.643        
  0                                                         0                             (0.0%)        0 (0.0%)     0 (0.0%)     0 (0.0%)     
  0.5                                                       8 (25.0%)                     10 (28.6%)    12 (37.5%)   9 (25.0%)                 
  1                                                         20 (62.5%)                    18 (51.4%)    16 (50.0%)   20 (55.6%)                
  2                                                         3 (9.4%)                      7 (20.0%)     4 (12.5%)    7 (19.4%)                 
  3                                                         1 (3.1%)                      0 (0.0%)      0 (0.0%)     0 (0.0%)                  
  Core features                                                                                                                                
  Fluctuating cognition                                     31 (96.9%)                    34 (97.1%)    30 (93.8%)   35 (97.2%)   0.856        
  Visual hallucination                                      28 (87.5%)                    28 (80.0%)    26 (81.3%)   29 (80.6%)   0.845        
  Parkinsonism                                              28 (87.5%)                    31 (88.6%)    27 (84.4%)   29 (80.6%)   0.781        
  Hoehn & Yahr                                                                                                                                 
  I                                                         5 (15.6%)                     5 (14.3%)     2 (6.3%)     5 (13.9%)                 
  II                                                        7 (21.9%)                     14 (40.0%)    12 (37.5%)   9 (25.0%)                 
  III                                                       16 (50.0%)                    12 (34.3%)    13 (40.6%)   15 (41.7%)                
  IV, V                                                     0 (0.0%)                      0 (0.0%)      0 (0.0%)     0 (0.0%)                  
  Suggestive features                                       REM sleep behavior disorder   11 (34.4%)    17 (48.6%)   12 (37.5%)   12 (33.3%)   0.542
  Severe neuroleptic sensitivity                            3 (9.4%)                      1 (2.9%)      0 (0.0%)     3 (8.3%)     0.261        
  Supportive features                                                                                                                          
  Repeated falls and syncope                                8 (25.0%)                     7 (20.0%)     6 (18.8%)    8 (22.2%)    0.933        
  Transient loss of consciousness                           5 (15.6%)                     2 (5.7%)      4 (12.5%)    0 (0.0%)     0.083        
  Severe autonomic dysfunction                              7 (21.9%)                     5 (14.3%)     7 (21.9%)    8 (22.2%)    0.809        
  Hallucinations in other modalities                        10 (31.3%)                    14 (40.0%)    12 (37.5%)   17 (47.2%)   0.600        
  Systematized delusion                                     9 (28.1%)                     11 (31.4%)    11 (34.4%)   13 (36.1%)   0.905        
  Depression                                                11 (34.4%)                    16 (45.7%)    9 (28.1%)    19 (52.8%)   0.160        
  Low occipital perfusion[a](#tf1-1){ref-type="table-fn"}   18 (85.7%)                    19 (82.6%)    19 (82.6%)   18 (85.7%)                
  Low MIBG uptake[a](#tf1-1){ref-type="table-fn"}           6 (100.0%)                    7 (87.5%)     11 (91.7%)   7 (63.6%)                 
  Concomitant drugs                                                                                                                            
  L-dopa                                                    5 (15.6%)                     4 (11.4%)     9 (28.1%)    4 (11.1%)    0.202        
  Dopamine agonists                                         1 (3.1%)                      1 (2.9%)      1 (3.1%)     2 (5.6%)     0.924        
  Antidepressants                                           2 (6.3%)                      3 (8.6%)      1 (3.1%)     3 (8.3%)     0.796        
  Benzodiazepines                                           6 (18.8%)                     13 (37.1%)    6 (18.8%)    9 (25.0%)    0.254        

Data are mean (standard deviation) or number (%).

^a^Cerebral blood flow single photon emission computed tomography and MIBG myocardial scintigraphy were recommended but not mandatory. The former was available in 21, 23, 23, and 21 patients and the latter in 6, 8, 12, and 11 patients of the placebo, 3mg, 5mg, and 10mg groups, respectively.

CDR = Clinical Dementia Rating; MIBG = ^123^I-metaiodobenzylguanidine; REM = rapid eye movement.

###### 

Mean Changes in Clinical Variables from Baseline to Week 12 (Last Observation Carried Forward)

  Variable                           Group     Baseline    Change                                                                                     
  ---------------------------------- --------- ----------- ------------- ------------ -------------------- ---------------------- --------- --------- --
  MMSE                               Placebo   32          18.3 (4.7)    0.271        31                   -0.4 (2.7)                                 
                                     3mg       35          20.4 (4.1)    35           1.6 (3.8)            2.0 (0.4 to 3.7)       0.017     0.013     
                                     5mg       32          19.8 (4.4)    32           3.4 (3.2)            3.8 (2.3 to 5.3)       \<0.001   \<0.001   
                                     10mg      36          19.8 (4.4)    36           2.0 (3.3)            2.4 (0.9 to 3.9)       0.001     \>0.001   
  WMS-R attention/concentration      Placebo   32          37.6 (11.3)   0.774        31                   -0.9 (7.9)                                 
                                     3mg       35          37.9 (13.8)   34           3.1 (9.9)            4.1 (-0.4 to 8.5)      0.074     0.090     
                                     5mg       32          40.5 (11.8)   32           5.6 (7.8)            6.5 (2.5 to 10.4)      0.001     0.002     
                                     10mg      34          38.2 (12.7)   33           4.8 (7.4)            5.7 (1.9 to 9.5)       0.003     0.002     
  Category fluency                   Placebo   32          7.2 (3.2)     0.170        31                   0.3 (3.4)                                  
                                     3mg       35          8.2 (3.1)     34           1.2 (4.0)            0.9 (-1.0 to 2.7)      0.341     0.144     
                                     5mg       32          8.6 (3.7)     32           1.6 (3.4)            1.3 (-0.5 to 3.0)      0.145     0.035     
  10mg                               36        9.1 (4.1)   35            -0.5 (2.7)   -0.8 (-2.3 to 0.7)   0.286                  0.905               
  Letter fluency                     Placebo   32          10.7 (6.2)    0.445        31                   0.3 (4.5)                                  
                                     3mg       35          10.2 (6.7)    34           1.1 (4.5)            0.8 ( -1.4 to 3.0)     0.474     0.461     
                                     5mg       32          11.5 (6.1)    32           3.1 (5.8)            2.8 (0.1 to 5.4)       0.038     0.005     
                                     10mg      36          12.6 (7.2)    35           1.7 (4.3)            1.4 (-0.7 to 3.6)      0.189     0.178     
  WAIS-III symbol digit modalities   Placebo   31          9.3 (8.2)     0.028        30                   0.3 (5.9)                                  
                                     3mg       35          15.5 (11.4)   34           6.4 (7.9)            6.1 (2.6 to 9.7)       \<0.001   \<0.001   
                                     5mg       32          15.9 (12.1)   32           6.9 (8.0)            6.6 (3.0 to 10.2)      \<0.001   \<0.001   
                                     10mg      34          17.9 (14.8)   33           3.7 (7.9)            3.4 (-0.1 to 7.0)      0.057     0.021     
  VPTA form recognition              Placebo   32          3.6 (3.3)     0.252        31                   -1.0 (2.9)                                 
                                     3mg       35          2.5 (3.6)     34           0.0 (2.7)            1.0 (-0.4 to 2.4)      0.145     0.167     
                                     5mg       32          2.0 (2.4)     32           -1.1 (2.4)           0.0 (-1.4 to 1.3)      0.964     0.426     
                                     10mg      35          2.7 (2.9)     34           -1.0 (2.1)           0.1 (-1.2 to 1.3)      0.921     0.568     
  NPI-10                             Placebo   32          18.3 (8.9)    0.079        32                   0.3 (17.5)                                 
                                     3mg       35          20.7 (12.8)   35           -3.9 (22.0)          -4.2 (-13.9 to 5.6)    0.396     0.602     
                                     5mg       32          14.0 (8.3)    32           -5.5 (6.7)           -5.8 (-12.4 to 0.8)    0.086     0.047     
                                     10mg      36          19.5 (12.8)   35           -8.0 (12.8)          -8.3 (-15.8 to -0.9)   0.029     0.019     
  NPI-2                              Placebo   32          6.3 (4.0)     0.443        32                   1.1 (5.7)                                  
                                     3mg       35          7.1 (4.1)     35           -2.1 (6.3)           -3.2 (-6.1 to -0.3)    0.032     0.025     
                                     5mg       32          6.3 (4.8)     32           -3.3 (3.8)           -4.4 (-6.8 to -2.0)    \<0.001   \<0.001   
                                     10mg      36          7.9 (5.4)     35           -4.6 (4.5)           -5.8 (-8.2 to -3.3)    \<0.001   \<0.001   
  NPI-4                              Placebo   32          12.1 (6.3)    0.269        32                   -0.3 (8.5)                                 
                                     3mg       35          11.5 (7.0)    35           -2.4 (10.8)          -2.1 (-6.9 to 2.6)     0.377     0.261     
                                     5mg       32          9.0 (5.3)     32           -4.2 (4.9)           -3.9 (-7.3 to -0.4)    0.028     0.008     
                                     10mg      36          11.9 (8.8)    35           -5.1 (7.4)           -4.8 (-8.7 to -1.0)    0.015     0.006     
  ZBI                                Placebo   32          21.8 (10.1)   0.197        31                   4.2 (10.4)                                 
                                     3mg       35          27.9 (13.9)   33           -1.3 (13.2)          -5.5 (-11.5 to 0.5)    0.069     0.301     
                                     5mg       32          22.9 (11.5)   31           -0.7 (15.7)          -4.9 (-11.7 to 1.8)    0.149     0.172     
                                     10mg      36          26.5 (16.1)   31           -5.0 (13.6)          -9.2 (-15.3 to -3.0)   0.004     0.035     
  UPDRS part III                     Placebo   33          20.8 (10.6)   0.702        31                   0.7 (3.8)                                  
                                     3mg       35          17.9 (9.0)    34           -0.5 (7.4)           -1.3 (-4.2 to 1.7)     0.393     0.397     
                                     5mg       33          19.1 (10.7)   32           -0.5 (5.4)           -1.3 (-3.6 to 1.1)     0.281     0.358     
                                     10mg      37          18.9 (11.6)   33           -1.0 (6.7)           -1.8 (-4.5 to 1.0)     0.200     0.258     

The significant differences in the analyses using mixed-effect model for repeated measures were consistent with those based on last observation carried forward for MMSE, NPI-10, and NPI-2: MMSE (3mg, *p* = 0.010; 5mg, *p* \< 0.001; 10mg, *p* = 0.003), NPI-10 (3mg, *p* = 0.115; 5mg, *p* = 0.160; 10mg, *p* = 0.028), NPI-2 (3mg, *p* = 0.003; 5mg, *p* \< 0.001; 10mg, *p* \< 0.001).

^a^Probability values are for the comparison between placebo and each active group.

^b^Significance level, *p* \<0.0167 (= 0.05/3 with Bonferroni correction).

ANCOVA = analysis of covariance; ANOVA = analysis of variance; CI = confidence interval; MMSE = Mini-Mental State Examination; NPI = Neuropsychiatric Inventory (NPI-10 = delusions - hallucinations - agitation/aggression - dysphoria - anxiety - euphoria - apathy - disinhibition - irritability/lability - aberrant motor behavior; NPI-2 = hallucinations - cognitive fluctuation; NPI-4 = delusions - hallucinations - dysphoria - apathy); SD = standard deviation; UPDRS =Unified Parkinson-s Disease Rating Scale; VPTA = Visual Perception Test for Agnosia; WAIS-III = Wechsler Adult Intelligence Scale; WMS-R = Wechsler Memory Scale-Revised; ZBI = Zarit Caregiver Burden Interview.

Cognitive Function {#ss3-2}
------------------

Mean changes in MMSE scores were significantly higher at the final evaluation (LOCF) in the 5 and 10mg groups (5mg, 3.4, *p* \< 0.001; 10mg, 2.0, *p* = 0.001) than in the placebo group (−0.4; see Table [2](#tbl2){ref-type="table"}, Fig [2](#fig02){ref-type="fig"}). When baseline values were adjusted as covariates, the difference between the 3mg and placebo groups was also significant. The results of the mixed-effect model analysis were consistent with those of LOCF analyses. The responder rate (MMSE change ≥3) was significantly higher in all donepezil groups (3mg, 42.9%, *p* = 0.013; 5mg, 65.6%, *p* \< 0.001; 10mg, 44.4%, *p* = 0.007) compared to placebo (12.9%). No dose dependency was demonstrated on trend analysis. On the WMS-R attention/concentration and WAIS-III symbol digit tests, significant improvements were also noted in each dose group compared to placebo. No significant improvement was detected on the verbal fluency and visuoperceptual tests.

![Mean changes from baseline in the (A) Mini-Mental State Examination and (B, C) Neuropsychiatric Inventory (B, NPI-10; C, NPI-2). Error bars represent standard deviation of the mean. LOCF = last observation carried forward.](ana0072-0041-f2){#fig02}

Behavioral and Neuropsychiatric Symptoms {#ss3-3}
----------------------------------------

Scores for NPI-2 and NPI-4 were significantly more improved at the final evaluation (LOCF) in the 5mg (except NPI-4) and 10mg groups than in the placebo group (see Table [2](#tbl2){ref-type="table"}, Fig [2](#fig02){ref-type="fig"}). When baseline values were adjusted as covariates, the difference in NPI-4 between the 5mg and placebo groups was significant. The difference in NPI-10 between each active group and placebo did not reach the significance level. The results of the mixed-effect model analyses were consistent with those of LOCF analyses. The trend analyses demonstrated a linear dose-dependent improvement for NPI-2 (linear, *p* = 0.036; 5mg saturation, *p* = 0.076) but not for NPI-4 and NPI-10.

The NPI-plus domains Delusion, Hallucination, and Cognitive Fluctuation improved in all active groups, whereas they deteriorated in the placebo group (Fig [3](#fig03){ref-type="fig"}). The differences between the placebo and both the 5 and 10mg groups were significant (5mg, *p* = 0.012, 0.014, and 0.004; 10mg, *p* = 0.002, \<0.001, and \<0.001 for each symptom, respectively).

![Mean changes (95% confidence intervals) of individual Neuropsychiatric Inventory items.](ana0072-0041-f3){#fig03}

Global Function {#ss3-4}
---------------

The distributions of CIBIC-plus at the final evaluation (LOCF) in all active groups were significantly superior to that of placebo (*p* \< 0.001 for each group; Table [3](#tbl3){ref-type="table"}). The responder rates were 33.3%, 68.8%, 71.0%, and 64.3% in the placebo, 3mg, 5mg, and 10mg groups, respectively. The differences from placebo were significant in the 3 and 5mg groups (3mg, *p* = 0.010; 5mg, *p* = 0.004; 10mg, *p* = 0.034). No dose dependency was demonstrated on trend analysis.

###### 

Distribution of the Clinician's Interview-Based Impression of Change plus Caregiver Input at Week 12 (Last Observation Carried Forward)

  Treatment Group   Total   Marked Improvement   Moderate Improvement   Minimal Improvement   No Change   Minimal Worsening   Moderate Worsening   Marked Worsening   Not Evaluable   *p*, Wilcoxon Rank Sum Test
  ----------------- ------- -------------------- ---------------------- --------------------- ----------- ------------------- -------------------- ------------------ --------------- -----------------------------
  Placebo           30      0 (0.0%)             1 (3.3%)               9 (30.0%)             5 (16.7%)   11 (36.7%)          4 (13.3%)            0 (0.0%)           0               
  3mg               32      1 (3.1%)             6 (18.8%)              15 (46.9%)            8 (25.0%)   1 (3.1%)            0 (0.0%)             1 (3.1%)           0               \<0.001
  5mg               31      5 (16.1%)            7 (22.6%)              10 (32.3%)            4 (12.9%)   3 (9.7%)            2 (6.5%)             0 (0.0%)           0               \<0.001
  10mg              28      2 (7.1%)             3 (10.7%)              13 (46.4%)            9 (32.1%)   1 (3.6%)            0 (0.0%)             0 (0.0%)           1               \<0.001

Percentages are based on the total number of evaluable patients in relevant treatment group. Probability values are for the comparison between placebo and each active group.

Caregiver Burden {#ss3-5}
----------------

ZBI score was reduced significantly more in the 10mg group than in placebo at the final evaluation (LOCF; *p* = 0.004), although the difference did not reach the significance level after baseline value adjustment (see Table [2](#tbl2){ref-type="table"}).

Safety {#ss3-6}
------

AEs were reported in 71%, 69%, 82%, and 87%, respectively, of the placebo, 3mg, 5mg, and 10mg groups (Table [4](#tbl4){ref-type="table"}). The majority were mild or moderate. The most common AE was elevated creatinine kinase (5.9%, 14.3%, 9.1%, and 13.5%, respectively). Cholinergic AEs such as diarrhea, nausea, anorexia, and abdominal discomfort were reported in some patients; however, no difference in incidence was noted between the placebo and any donepezil groups. Adverse parkinsonian events were reported in 2.9%, 8.6%, 12.1%, and 2.7%. The mean UPDRS part III score somewhat improved in all active groups at the final evaluation, whereas the score worsened in placebo, although the differences among groups did not reach the significance level (see Table [2](#tbl2){ref-type="table"}). Adverse behavioral events were 11.8%, 22.9%, 15.2%, and 8.1% in the placebo, 3mg, 5mg, and 10mg groups, respectively; nevertheless, these differences were not statistically significant. The proportions of AEs leading to withdrawal were similar between groups: 11.8%, 8.6%, 3.0%, and 8.1%, respectively. Serious AEs occurred in 5.9%, 5.7%, 6.1%, and 10.8% of the respective groups. Of these, only 2 events, agitation in the placebo group and subarachnoid hemorrhage in the 3mg group, were judged to be related to the study drug. One serious AE in the 10mg group (worsening of hallucinations) occurred while the patient was still taking 3mg/day during the titration period. There were no clinically relevant differences in vital signs or electrocardiogram between the groups.

###### 

Adverse Events

  AEs                          Placebo, n = 34   3mg, n = 35               5mg, n = 33               10mg, n = 37                                                          
  ---------------------------- ----------------- ------------------------- ------------------------- ------------------------- ---------- ---------- ---------- ---------- ----------
  Total                        24 (70.6%)        24 (68.6%), *p* = 1.000   27 (81.8%), *p* = 0.391   32 (86.5%), *p* = 0.146                                               
  Severe AEs                   2 (5.9%)          1 (2.9%)                  0 (0.0%)                  1 (2.7%)                                                              
  Serious AEs                  2 (5.9%)          2 (5.7%)                  2 (6.1%)                  4 (10.8%)                                                             
  AEs leading to withdrawal    4 (11.8%)         3 (8.6%)                  1 (3.0%)                  3 (8.1%)                                                              
  Gastrointestinal disorders   8 (23.5%)         1 (2.9%), *p* = 0.013     10 (30.3%), *p* = 0.589   13 (35.1%), *p* = 0.310   Anorexia   0 (0.0%)   1 (2.9%)   0 (0.0%)   2 (5.4%)
  Diarrhea                     4 (11.8%)         0 (0.0%)                  4 (12.1%)                 3 (8.1%)                                                              
  Abdominal discomfort         1 (2.9%)          0 (0.0%)                  2 (6.1%)                  0 (0.0%)                                                              
  Nausea                       1 (2.9%)          0 (0.0%)                  0 (0.0%)                  2 (5.4%)                                                              
  Vomiting                     1 (2.9%)          0 (0.0%)                  0 (0.0%)                  1 (2.7%)                                                              
  Parkinson symptoms           1 (2.9%)          3 (8.6%), *p* = 0.613     4 (12.1%), *p* = 0.197    1 (2.7%), *p* = 1.000                                                 
  Psychiatric symptoms         4 (11.8%)         8 (22.9%), *p* = 0.341    5 (15.2%), *p* = 0.733    3 (8.1%), *p* = 0.702                                                 

Probability values are for the comparison between placebo and each active group.

Discussion {#ss4}
----------

In the present study, we found that donepezil improved both cognition and behavior in patients with DLB compared to placebo. Patients given 5 or 10mg donepezil showed greater improvement in the majority of the cognitive and behavioral measures, including the MMSE and NPI. Donepezil treatment also led to improved global function and reduced caregiver burden in this population. Because consistent improvements in many different measures across broad domains were observed, despite the exploratory nature of this study due to several limitations as discussed below, we believe that our findings demonstrated encouraging effects of donepezil for patients with DLB.

The majority of cognitive measures showed significant between-group differences. In particular, there was an apparent improvement in overall cognitive function, especially with the higher 2 doses; the mean changes in MMSE score favored donepezil by 2.0 to 3.8 points. This difference was larger than that reported in other studies of ChEIs in DLB, AD, and Parkinson disease with dementia (PDD).[@b15], [@b32], [@b33] Improvement was also noted in the attentive-executive domains. We presume that a ceiling effect caused the nonsignificant outcome in the visuoperceptual domain.

Also noteworthy was the improvement of neuropsychiatric features and reduction of caregiver burden in the donepezil groups. The beneficial effect of donepezil was evident on each symptom domain characteristic of DLB (delusion, hallucination, and cognitive fluctuation), as generally consistent with the previous rivastigmine study[@b15] except for apathy. For NPI-2, a linear dose-response relationship was demonstrated. Caregiver burden also was reduced significantly at the highest dose, 10mg/day.

Patients who received donepezil also demonstrated improved global function, as measured by CIBIC-plus. A higher percentage of patients showed improvement, and fewer patients worsened in each donepezil group than in placebo. The beneficial effect seemed greater than those of ChEIs reported for patients with AD and PDD.[@b33; @b34; @b35] In a trial of rivastigmine for PDD, improvement of activities of daily living, which would reflect treatment-induced changes in cognitive, behavioral, and motor symptoms, was reported.[@b33] Such an outcome may also be useful to compare the clinically meaningful impacts of the treatment among trials.

AEs were not rare; however, only approximately 8% of the study population withdrew due to AEs, and the prevalence of withdrawal or AEs, including typical cholinergic side effects, did not differ among treatment groups. Although symptoms of parkinsonism were reported as AEs somewhat more frequently in the 3 and 5mg groups than in the placebo group, the difference was not reflected in the mean UPDRS part III score. Indeed, the score demonstrated numerical, although nonsignificant, improvement in the highest dose group. Cholinergic treatment theoretically exacerbates parkinsonism. However, the possible beneficial effects of donepezil observed in this study suggest that the use of ChEIs should not necessarily be avoided in the treatment of DLB due to concern of possible parkinsonism. These unexpected effects, despite not being confirmed, might be explained by a complicated neuronal network for motor control.

As the discontinuation rate was relatively low, and there was no significant difference among groups, it is unlikely that exclusion bias caused by early termination affected the efficacy results. Both the LOCF analysis and the mixed-effect model analysis consistently showed favorable results.

As an aim of this study was to explore targetable clinical presentations of DLB, we did not set a specific primary endpoint despite assigning multiple efficacy outcome measures, which could be a major limitation. In addition, cognitive fluctuation was measured by an unestablished tool, which is well equipped but not yet validated. Another limitation is that nearly half of the centers enrolled only 1 or 2 patients, which may have caused an inter-rater discordance of the clinical ratings, although a training and certification course was mandatory for the investigators. Also, the small sample, short duration of treatment, and lack of formal dose-response comparison are evident limitations. Nevertheless, the results of this study strongly suggest that donepezil is safe in patients with DLB, and provide a preliminary indication of its clinical effectiveness in terms of cognitive function, behavioral symptoms, and global function of DLB, and consequently in effecting a reduction of caregiver burden. The findings of the present study with donepezil should be verified in a confirmatory clinical trial. In addition, long-term effects should be examined. Although both 5mg/day and 10mg/day seemed to be beneficial, 10mg/day was somewhat more beneficial in terms of behavioral symptoms. The optimum dose should be determined in a follow-up trial, in which dose titration with patients unable to tolerate 10mg/day being allowed to take 5mg/day would be a sensible design.
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